Screener
Axsome Therapeutics AXSM EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
FAQ
- What is Axsome Therapeutics's EBITDA margin?
- Axsome Therapeutics (AXSM) reported EBITDA margin of -23.5% in Q1 2026.
- How has Axsome Therapeutics's EBITDA margin changed year-over-year?
- Axsome Therapeutics's EBITDA margin increased by 61.5% year-over-year, from -60.9% to -23.5%.
- What is the long-term trend for Axsome Therapeutics's EBITDA margin?
- Over 3 years (2022 to 2025), Axsome Therapeutics's EBITDA margin has grown at a -58.5% compound annual growth rate (CAGR), from -350.5% to -25%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Axsome Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude